10.1 Revascularization for Limb Salvage

10.1 Revascularization for Limb Salvage

Core Clinical Principle: Definitive surgical wound closure—whether by secondary intention, split-thickness skin grafting, or local tissue rearrangement—is biologically impossible without verified macrovascular arterial inflow and capillary perfusion. The Certified Wound Specialist Physician (CWSP) must orchestrate the precise sequence between revascularization, radical debridement, and reconstructive coverage to achieve durable limb salvage in chronic limb-threatening ischemia (CLTI).

Tissue loss in the diabetic and neuropathic lower extremity frequently develops against a background of severe peripheral arterial disease (PAD), extensive medial arterial calcification, and microvascular dysfunction. Salvaging a threatened extremity requires the clinician to integrate noninvasive hemodynamics, the multi-axial Society for Vascular Surgery (SVS) WIfI classification, angiosome anatomy, endovascular versus open surgical bypass indications, and the hierarchical reconstructive ladder.

---

Hemodynamic Triggers for Revascularization

Ischemia represents an absolute biological impediment to wound repair. While healthy dermis maintains a microvascular oxygen tension ($TcPO_2$) of 50 to 70 mmHg, reparative cellular cascades (including neutrophil oxidative bactericidal killing, fibroblast collagen hydroxylation, and endothelial capillary budding) stall completely when tissue perfusion falls below critical hemodynamic thresholds.

+-------------------------------------------------------------------------------------------------+
|                      HEMODYNAMIC CRITERIA FOR CHRONIC LIMB-THREATENING ISCHEMIA (CLTI)           |
+-------------------------------------------------------------------------------------------------+
| CRITICAL LIMB ISCHEMIA / SEVERE HYPOPERFUSION:                                                  |
|   • Ankle-Brachial Index (ABI): about 0.40 or less, or absolute ankle pressure < 50 mmHg          |
|   • Absolute toe systolic pressure < 30 mmHg (WIfI Ischemia grade 3)                             |
|   • Transcutaneous Oxygen Tension (TcPO2): < 30 mmHg (Severe Microvascular Tissue Hypoxia)      |
|   • Skin Perfusion Pressure (SPP): < 30-40 mmHg                                                 |
|   • Clinical Manifestation: Rest pain, non-healing ischemic ulceration, or gangrene              |
|   • MANDATE: Immediate vascular surgical consultation for arterial revascularization            |
+-------------------------------------------------------------------------------------------------+

Attempting aggressive sharp debridement, applying advanced cellular biologics, or performing primary wound closure on a severely ischemic limb (for example, toe pressure <30 mmHg) without first evaluating for revascularization is generally inappropriate. Without restoring pulsatile perfusion, surgical incisions dehisce, debridement margins become necrotic, and the patient faces rapid proximal amputation.

---

Endovascular Interventions vs. Open Surgical Bypass

Restoring arterial perfusion to the pedal arch is achieved through either percutaneous catheter-based endovascular techniques or open surgical bypass grafting. Determining the optimal revascularization strategy depends on patient operative risk, anatomical lesion complexity, and the availability of adequate autologous venous conduit.

+-------------------------------------------------------------------------------------------------+
|                         REVASCULARIZATION MODALITY COMPARISON MATRIX                            |
+-------------------------------------------------------------------------------------------------+
| ENDOVASCULAR REVASCULARIZATION                                                                  |
|   • Techniques: Percutaneous transluminal angioplasty (PTA), drug-coated balloons (DCB),        |
|     bare-metal stents (BMS), drug-eluting stents (DES), and atherectomy (directional,           |
|     rotational, orbital, or excimer laser atherectomy).                                         |
|   • Indications: High-risk surgical candidates, focal stenoses or short occlusions (TASC A & B),|
|     isolated iliac or superficial femoral artery (SFA) lesions, or absence of autologous vein.  |
|   • Advantages: Minimally invasive; percutaneous local anesthesia; low cardiopulmonary stress;  |
|     rapid procedural recovery; immediate restitution of flow; repeatable; preserves bypass beds.|
|   • Limitations: Elastic recoil, flow-limiting dissections, high restenosis rates in long       |
|     calcified infrapopliteal lesions (TASC D), and variable durability in chronic total          |
|     occlusions (CTOs).                                                                          |
+-------------------------------------------------------------------------------------------------+
                                                VS
+-------------------------------------------------------------------------------------------------+
| OPEN SURGICAL BYPASS GRAFTING                                                                   |
|   • Conduits: Single-segment autologous Greater Saphenous Vein (GSV) [Gold Standard], spliced   |
|     veins (lesser saphenous, arm cephalic/basilic veins), or prosthetic PTFE / Dacron grafts.   |
|   • Indications: Long diffuse multi-level occlusions, flush superficial femoral artery or       |
|     tibial chronic total occlusions (TASC C & D), extensive tissue loss (WIfI Stage 3 or 4),    |
|     good operative surgical risk, and verified suitable autologous vein conduit.                |
|   • Advantages: Superior long-term primary and secondary patency (>75-80% at 5 years for vein), |
|     durable hemodynamics delivering robust multi-vessel runoff, excellent limb salvage.          |
|   • Limitations: Significant surgical morbidity (groin/leg incision dehiscence, harvest wound   |
|     infections, systemic cardiac events), longer recovery, dependent on autologous vein caliber |
|     (>= 3.0 mm); prosthetic PTFE bypass to infrapopliteal targets yields dismal patency.        |
+-------------------------------------------------------------------------------------------------+

---

Landmark Clinical Trial Evidence: BEST-CLI & BASIL-2

Two landmark multicenter randomized controlled trials have reshaped contemporary clinical guidelines regarding the choice between surgical bypass and endovascular therapy in CLTI:

1. The BEST-CLI Trial (Best Endovascular vs. Best Surgical Therapy in Patients with Critical Limb Ischemia)

Published in the New England Journal of Medicine (2022), BEST-CLI enrolled patients with CLTI across two parallel international cohorts:

• Cohort 1 (Patients with an Adequate Single-Segment Great Saphenous Vein): Surgical bypass reduced the primary composite outcome of major adverse limb events (above-ankle amputation or major reintervention) or death (hazard ratio 0.68, a 32% relative reduction), driven mainly by far fewer major reinterventions. Above-ankle amputations were numerically lower with bypass (hazard ratio 0.73, confidence interval reaching 1.00), and mortality was similar.
• Cohort 2 (Patients Lacking an Adequate Autologous Saphenous Vein): In patients requiring alternative conduits, the primary outcome did not differ significantly between surgical bypass and endovascular therapy.
• Clinical Guideline Impact: In surgically eligible candidates presenting with CLTI who possess an adequate single-segment GSV, open surgical vein bypass is the superior, first-line revascularization strategy.

2. The BASIL-2 Trial (Bypass Versus Angioplasty in Severe Ischaemia of the Leg - 2)

Published in The Lancet (2023), BASIL-2 randomized patients with CLTI who needed an infrapopliteal revascularization (with or without more proximal infrainguinal disease) to vein bypass first or best endovascular treatment first:

• An endovascular-first strategy was associated with better amputation-free survival than a vein bypass-first strategy, a difference driven largely by more deaths in the bypass group during follow-up; major amputation rates were similar.
• Synthesis for Clinical Practice: The trials studied different populations. Surgically fit patients with good saphenous vein (BEST-CLI cohort 1) did better with bypass, whereas patients needing infrapopliteal revascularization in BASIL-2 did better with an endovascular-first strategy; decisions weigh anatomy, conduit, frailty, and life expectancy.

---

Greater Saphenous Vein (GSV) Conduit Criteria

The autologous great saphenous vein is the preferred conduit for infrainguinal and infrapopliteal surgical bypass. Before undertaking surgical bypass, duplex ultrasound vein mapping must verify that the GSV satisfies strict anatomical and morphological criteria:

+=================================================================================================+
|                         AUTOLOGOUS GSV CONDUIT EVALUATION CRITERIA                              |
+=================================================================================================+ 
| 1. LUMINAL CALIBER (DIAMETER)                                                                   |
|    • Ideal: Internal diameter >= 3.5 mm under physiological hydrostatic dilation                |
|    • Acceptable Minimum: >= 3.0 mm throughout the entire length of the conduit                   |
|    • Inadequate: Luminal caliber < 2.5 to 3.0 mm is associated with early graft thrombosis,     |
|      high resistance, and unacceptable 1-year failure rates (>60-70% failure).                  |
+-------------------------------------------------------------------------------------------------+
| 2. MORPHOLOGICAL INTEGRITY & WALL QUALITY                                                       |
|    • Must be completely compressible with thin, compliant walls.                                |
|    • Disqualifying Features: Intraluminal synechiae, web-like trabeculations from prior deep/   |
|      superficial thrombophlebitis, wall thickening, calcification, or varicosities.             |
+-------------------------------------------------------------------------------------------------+
| 3. CONTINUITY                                                                                   |
|    • Continuous, single-segment ipsilateral GSV is the gold standard.                           |
|    • Spliced conduits (combining contralateral GSV, small saphenous, or arm cephalic/basilic    |
|      veins) introduce more anastomoses and are associated with lower long-term patency.        |
+=================================================================================================+

Surgical Bypass Configurations

• Reversed Vein Graft: The harvested saphenous vein is excised, reversed end-for-end (so that venous valves do not impede arterial forward flow), and tunneled anatomically. Limitation: The larger proximal saphenous end is sewn to the smaller distal tibial artery, creating an unfavorable hemodynamic caliber mismatch.
• In-Situ Vein Graft: The vein remains in its native subcutaneous bed, disconnecting only the proximal and distal ends. A mechanical valvulotome is introduced intraluminally to incise and disrupt the venous valve cusps, allowing arterial flow down the unreversed vein. Side branches must be meticulously ligated to prevent arteriovenous fistulas. Advantage: Preserves natural caliber tapering (larger vein proximally at the femoral artery; smaller vein distally at the tibial artery).
• Non-Reversed Translocated Vein: The vein is harvested, valves are excised with a valvulotome under direct visualization, and the graft is relocated to the contralateral limb or opposite compartment.

The Problem with Prosthetic (PTFE) Grafts Below the Knee

When autologous vein is unavailable, synthetic polytetrafluoroethylene (PTFE) or Dacron grafts may be utilized for above-knee femoropopliteal bypass (yielding acceptable 5-year patency of 60–70%). However, for infrapopliteal (tibial or pedal) targets, prosthetic grafts perform dismally, with 2-year primary patency rates dropping below 30% to 40% due to progressive compliance mismatch, intimal hyperplasia at the distal anastomosis, and surface thrombogenicity. If no autologous vein is present, complex endovascular recanalization is strongly preferred over infrapopliteal prosthetic bypass.

---

The Angiosome Model of Foot Perfusion

First described by Taylor and Palmer in 1987 and applied to diabetic limb salvage by Attinger, the angiosome concept divides the foot and ankle into six discrete three-dimensional vascular territories supplied by specific branches of the three primary infrapopliteal trunk arteries (Anterior Tibial, Posterior Tibial, and Peroneal):

+-------------------------------------------------------------------------------------------------+
|                                 THE SIX FOOT & ANKLE ANGIOSOMES                                 |
+-------------------------------------------------------------------------------------------------+
| 1. ANTERIOR TIBIAL ARTERY (ATA) / DORSALIS PEDIS                                                |
|    • Anatomical Territory: Anterior ankle compartment, dorsum of foot, and dorsal digits.       |
|    • Target Ulcers: Dorsal foot ulcers, anterior ankle pressure injuries, dorsal toe necrosis.  |
+-------------------------------------------------------------------------------------------------+
| 2. POSTERIOR TIBIAL ARTERY (PTA) - MEDIAL CALCANEAL BRANCH                                      |
|    • Anatomical Territory: Medial aspect of heel and posterior weight-bearing plantar heel.     |
|    • Target Ulcers: Medial calcaneal pressure injuries and decubitus heel fissures.             |
+-------------------------------------------------------------------------------------------------+
| 3. POSTERIOR TIBIAL ARTERY (PTA) - MEDIAL PLANTAR BRANCH                                        |
|    • Anatomical Territory: Medial plantar instep, medial arch, and plantar aspect of hallux.    |
|    • Target Ulcers: Medial midfoot Charcot ulcers and first metatarsophalangeal plantar ulcers. |
+-------------------------------------------------------------------------------------------------+
| 4. POSTERIOR TIBIAL ARTERY (PTA) - LATERAL PLANTAR BRANCH                                       |
|    • Anatomical Territory: Lateral sole, central plantar vault, and forefoot (met heads 2-5).  |
|    • Target Ulcers: Sub-metatarsal head ulcers (rays 2 through 5) and lateral plantar sole.     |
+-------------------------------------------------------------------------------------------------+
| 5. PERONEAL ARTERY - CALCANEAL BRANCH                                                           |
|    • Anatomical Territory: Lateral aspect of the heel and posterior lateral rearfoot.           |
|    • Target Ulcers: Lateral heel decubitus ulcers and lateral retromalleolar wounds.            |
+-------------------------------------------------------------------------------------------------+
| 6. PERONEAL ARTERY - ANTERIOR PERFORATING BRANCH                                                |
|    • Anatomical Territory: Anterolateral ankle, lateral malleolus, lateral dorsum of rearfoot.  |
|    • Target Ulcers: Lateral malleolar pressure injuries and anterolateral supramalleolar wounds.|
+=================================================================================================+

Direct vs. Indirect Angiosome Revascularization

• Direct Angiosome Revascularization: Re-establishing straight, pulsatile, in-line arterial flow directly into the specific feeding artery that supplies the anatomical territory of the wound. Observational studies and meta-analyses associate direct angiosome revascularization with faster healing and better limb salvage than indirect revascularization, although results vary and randomized evidence is lacking.
• Indirect Revascularization via Collaterals: Restoring flow through an adjacent angiosome artery that communicates with the wound bed via collaterals (e.g., revascularizing the anterior tibial artery for a plantar heel ulcer supplied by the posterior tibial artery).
• The Pedal Arch & Collateral Choke Vessels: Indirect revascularization can achieve limb salvage only if robust collateral pathways—specifically the pedal arch (the deep plantar communicating artery connecting the dorsalis pedis and the lateral plantar artery)—remain widely patent. In patients with end-stage renal disease (ESRD) or longstanding diabetes, calcification and microvascular disease obliterate these small "choke vessels," causing indirect revascularization to fail. Whenever technically feasible, direct angiosome revascularization must be prioritized.

---

The SVS WIfI Classification System

To replace outdated single-variable classifications (such as Fontaine or Rutherford), the Society for Vascular Surgery (SVS) established the WIfI (Wound, Ischemia, and foot Infection) classification. WIfI stratifies the three primary drivers of limb loss into independent grades from 0 to 3:

+=================================================================================================+
|                             SVS WIfI SCORING SYSTEM (GRADES 0 TO 3)                             |
+=================================================================================================+
| PARAMETER    | GRADE 0           | GRADE 1           | GRADE 2           | GRADE 3              |
+--------------+-------------------+-------------------+-------------------+----------------------+
| WOUND (W)    | No ulcer          | Small, shallow    | Deeper ulcer with | Extensive, deep      |
|              | (pure ischemic    | ulcer on distal   | exposed bone,     | ulcer; extensive     |
|              | rest pain);       | leg or foot;      | tendon, or joint; | gangrene extending   |
|              | no gangrene       | no exposed tendon/| shallow ulcer with| into midfoot/hindfoot|
|              |                   | bone; no gangrene | gangrene on digits| non-salvageable ray  |
+--------------+-------------------+-------------------+-------------------+----------------------+
| ISCHEMIA (I) | ABI >= 0.80       | ABI 0.60 - 0.79   | ABI 0.40 - 0.59   | ABI < 0.40           |
|              | Ankle Press >100  | Ankle 70 - 100    | Ankle 50 - 70     | Ankle Press < 50     |
|              | Toe P >= 60 mmHg  | Toe P 40 - 59     | Toe P 30 - 39     | Toe P < 30 mmHg      |
|              | TcPO2 >= 60 mmHg  | TcPO2 40 - 59     | TcPO2 30 - 39     | TcPO2 < 30 mmHg      |
+--------------+-------------------+-------------------+-------------------+----------------------+
| FOOT         | Uninfected;       | Mild: Erythema    | Moderate: Erythema| Severe: Local        |
| INFECTION    | no purulence or   | <= 2 cm around    | > 2 cm or deep    | infection with >= 2  |
| (fI)         | inflammation      | ulcer; superficial| structures (bone/ | SIRS criteria        |
|              |                   | only; no SIRS     | tendon); no SIRS  | (sepsis / toxicity)  |
+=================================================================================================+

Clinical Staging & Outcome Prediction

By integrating the individual W, I, and fI grades, patients are assigned to one of four composite Clinical Stages:

• Stage 1: Very low estimated 1-year amputation risk.
• Stage 2: Low estimated risk.
• Stage 3: Moderate estimated risk.
• Stage 4: High estimated risk.

In a pooled review of validation cohorts, weighted 1-year major amputation rates were roughly 3%, 7%, 9%, and 25% for stages 1–4. A separate matrix estimates the benefit of revascularization, which rises with the ischemia grade.

WIfI Clinical Pearl: Even a small superficial ulcer (W-1) with moderate infection (fI-2) falls in Stage 4 when ischemia is severe (I-3, toe pressure <30 mmHg), and urgent vascular evaluation is needed.

---

Timing of Surgical Reconstruction & Reperfusion Physiology

Following successful arterial revascularization, definitive surgical reconstruction (e.g., skin grafting, rotational flaps, or amputation closure) is usually staged rather than performed immediately, although urgent debridement of infection should not wait:

+-------------------------------------------------------------------------------------------------+
|                     STAGED RECONSTRUCTION PROTOCOL POST-REVASCULARIZATION                       |
+-------------------------------------------------------------------------------------------------+
| DAY 0: SUCCESSFUL REVASCULARIZATION (Bypass or Endovascular)                                    |
|   • Immediate restoration of pulsatile macrovascular inflow.                                    |
|   • Microvascular capillary loops are chronically dilated, hyperpermeable, and fragile.         |
+-------------------------------------------------------------------------------------------------+
                                                │
                                                ▼
+-------------------------------------------------------------------------------------------------+
| HOURS 24 TO 72: REPERFUSION INFLAMMATION & TISSUE STABILIZATION                                 |
|   • Massive influx of oxygen generates reactive oxygen species (ROS) -> Endothelial swelling.   |
|   • Marked dependent reperfusion edema develops, increasing interstitial tissue pressure.       |
|   • Microvascular perfusion equilibrates; non-viable tissue clearly demarcates from viable bed. |
|   • Management: Elevate slightly or keep neutral; maintain non-adherent protective dressings.   |
+-------------------------------------------------------------------------------------------------+
                                                │
                                                ▼
+-------------------------------------------------------------------------------------------------+
| DAYS TO WEEKS LATER: DEFINITIVE DEBRIDEMENT & RECONSTRUCTION (Timing Individualized)            |
|   • Perfusion reassessed objectively (pulses, Doppler, toe pressure, or TcPO2).                  |
|   • Debride demarcated necrotic tissue to a viable, bleeding base.                                |
|   • Execute definitive reconstruction: STSG, FTSG, or vascularized local/muscle flap.           |
+-------------------------------------------------------------------------------------------------+

Leg edema is common after infrainguinal bypass, reflecting reperfusion of chronically dilated capillary beds plus lymphatic disruption during exposure and vein harvest. Grafting into an edematous, hyperemic bed raises the risk of seroma, hematoma, and graft loss. Perfusion gains after endovascular therapy can take days to weeks to reach their peak, which also argues for reassessing before definitive closure.

---

Clinical Trap

Clinical Trap 1: Debriding an Ischemic Ulcer Before Revascularization

Aggressive excisional debridement of a dry, uninfected gangrenous toe in a patient with an ABI of 0.35 and toe pressure of 18 mmHg can turn stable dry gangrene into a larger non-healing wound or a wet, limb-threatening infection. Practice Point: In severe ischemia without infection, keep dry gangrene dry and protected (often painted with povidone-iodine) until revascularization has been evaluated or completed.